Elenco degli articoli con argomento «psoriasi»
Dermatologia07 gen 2020
Development and preliminary validation of the Adolescent Psoriasis Quality of Life instrument (APso‐QOL)
a disease‐specific measure of quality of life in adolescents with psoriasis
09 dic 2019
Psoriasi: conosciuta ma decisamente sottotrattata. E i pazienti vivono in preda all’ansia
Sono i risultati scaturiti da due studi presentati a Madrid dove in questi giorni è in corso il 28° congresso dell’EADV.
09 dic 2019
Prurito: che cosa lo può provocare, come si controlla e quando è spia di problemi seri
Se si escludono le punture di insetti, nella maggior parte dei casi la ragione di quell’impulso è da ricercare in una patologia dermatologica. Ma anche in alcune abitudini scorrette e malattie sistemiche
09 dic 2019
Predictors of hospital readmission in US adults with psoriasis
Readmission in Psoriasis
02 dic 2019
Psoriasi: fototerapia da preferire contro il dolore
Psoriasi, fototerapia meglio di adalimumab nel migliorare dolore e qualità di vita secondo uno studio pubblicato sul Journal of American Academy of Dermatology
17 nov 2019
Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children
Psoriasis is a chronic, multifactorial, inflammatory disorder, with an estimated prevalence of 0.71% in children.
29 ott 2019
Skin changes in the obese patient
Obesity is a worldwide major public health problem with an alarmingly increasing prevalence over the past 2 decades.
29 ott 2019
Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study.
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.
15 ott 2019
Psoriasi: farmaci biologici sempre più efficaci e sicuri
Gli anticorpi migliorano significativamente i sintomi della malattia. No al “fai da te”. Sul web troppi video privi di contenuto scientifico
08 ott 2019
La psoriasi è la malattia dei sani
E' vero che ... La psoriasi è la malattia dei sani
25 set 2019
Dietary compounds as potential modulators of microRNA expression in psoriasis
This review aims to summarize knowledge about aberrant microRNAs expression in psoriasis
11 set 2019
Psoriasi a placche, Fda approva farmaco per l'uso negli adolescenti dai 12 anni di età
La Food and Drug Administration (FDA) degli Stati Uniti ha approvato calcipotriene 0,005% formulato in schiuma, commercializzato da Mayne Pharma Group, per il trattamento della psoriasi a placche del cuoio capelluto e del corpo negli adolescenti di almeno 12 anni di età.
03 set 2019
Effects of psoriasis treatment on genital warts: a case report.
The use of immunosuppressive drugs predisposes to infections, as they block the most important stage in antiviral defense, which is the cytotoxic T-lymphocyte HLA-dependent response.
03 set 2019
Relapse of psoriasis in patients who asked to discontinue etanercept after achieving a stable clinical remission.
There is increasing interest in discontinuing biological therapies in patients with chronic plaque psoriasis (PsO) who achieve a complete clinical remission, provided patients maintain clinical benefit.
24 lug 2019
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis
2019 May 24;9:29-35. doi: 10.2147/PTT.S179283. eCollection 2019.
07 giu 2019
Non trattare la pelle con superficialità
Campagna informativa
25 mag 2019
Task Force "Psoriasi nella donna in età fertile” al WCD
Interventi del gruppo Psoriasi al Word Congress of Dermatology
22 mag 2019
Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives.
Psoriasis affects 2-4% of the world’s population
14 mag 2019
Safety and efficacy of Certolizumab Pegol in a real-life cohort of patients with Psoriasis and Psoriatic Arthritis
Aim of this observational study was to assess safety and efficacy of Certolizumab Pegol(CZP) in a real-life cohort of patients affected by psoriasis(PsO) and psoriatic arthritis(PsA), who had an inadequate response to previous systemic immunosuppressive treatments, with a follow-up of 24 weeks.
14 mag 2019
Ultrasound assessment of the keratolitic effect of a 50% urea anhydrous paste on psoriasis plaques: a prospective study
The keratolytic effect of urea is well-known, although the majority of the available studies rely on clinical observation only. The aim of this open trial was to evaluate, through clinical and ultrasound assessment, the efficacy and tolerability of a 50% urea anhydrous paste on hyperkeratotic psoriatic plaques